RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th [Yahoo! Finance]
RenovoRx, Inc. (RNXT)
Company Research
Source: Yahoo! Finance
life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will be participating at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum , to be held on November 20, 2025. Mr. Bagai will share an update on RenovoRx's commercialization progress, driven by strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. He will also highlight the latest developments from the Company's ongoing Phase III TIGeR-PaC clinical trial , evaluating RenovoRx's novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath known as IAG) in locally advanced pancreatic cancer (LAPC). In addition, Mr. Bagai will discuss the Company's recently launched post-marketing observational registry study designed t
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9thGlobeNewswire
- RenovoRx (NASDAQ:RNXT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- RenovoRx (NASDAQ:RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $12.00 to $12.50. They now have a "buy" rating on the stock.MarketBeat
- RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20thGlobeNewswire
- RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]Yahoo! Finance
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 11/24/25 - Form 4
- 11/14/25 - Form 8-K
- 11/14/25 - Form 424B5
- RNXT's page on the SEC website